Syncona Focuses On Creating Commercially Ambitious Businesses

With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.

Video interview

During the 2017 BIO-Europe partnering meeting in Berlin, Germany, Syncona's Iraj Ali talks to Informa Pharma Intelligence’s Mike Ward about the investment group’s funding sweet spots.

Syncona Limited was formed in December 2016 when BACIT (formerly Battle Against Cancer Investment Trust) acquired Syncona Partners LLP to form an investment company valued at more than £850m; Syncona Partners LLP was founded as an independent subsidiary of the Wellcome

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business